(344) Local Extended-Release Colchicine for Intra-Articular Treatment of Gout Flares
Introduction: Gout is a common and very painful form of arthritis, however current gout flares therapies are limited by suboptimal efficacy and safety concerns [1][2]. Oral colchicine, for example, is associated with major systemic side effects that constrain its clinical utility. This highlights a pressing need for safer and more effective therapeutic options. To that end, we developed an intra-articular colchicine dosage form, enhancing efficacy in the joint while avoiding systemic toxicity. This approach is based on extended-release PLGA microspheres tailored for intra-articular injection (Figure 1).
Learning Objectives:
describe the main limitation of the current drug therapies for gout flares
compare the efficacy and safety of a local colchicine dosage form versus an oral administration
assess the potential of drug reformulation for a local administration
Farah Marzouki – Head of pharmaceutical development, PK MED, France; Charles Sanson – Head of R&D, PK MED, France; Julien Grassot – Head of Clinical Development, PK MED, France; Philippe Pouletty – Board administrator, PK MED, France; Elodie Rivière – Professor of Rheumatology, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France; Marie-Christophe Boissier – Professor of Rheumatology, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France
